A Risky Bet on Rare Disease Treatment Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences marks a significant bet on a rare form of epilepsy treatment.
ABS 1230, the clinical stage drug in question, has shown promising results in early trials, including a proof of concept study where children experienced meaningful seizure reductions.
The FDA's granting of various designations – Orphan Drug, Rare Pediatric Disease, and Fast Track – lends credibility to Actio Biosciences' work. This acquisition comes at a crucial juncture for Jazz Pharmaceuticals.